The No. 1 stock on this list has more than half its float short.
Sales of the prescription fish-oil are so low that generic drug makers may simply pass the product by.
The decision to change out the primary and secondary endpoints was made as part of discussions with the FDA, a Vertex spokesman said.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech investing goes mainstream.
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Read what doctors not involved in Prana's PBT2 study had to say about the results announced Tuesday.
Northera treats a rare condition which causes low blood pressure upon standing.
In which I engage in a Twitter spat with a Harvard professor about Prana Bio's Huntington disease drug.
The new BioMarin drug, Vimizin, is expected to generate $60-70 million in sales this year.